Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Thiazolidinediones398 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A25887 | 21352073 | Expert Opin Emerg Drugs | Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. | 2011 | Details |
| A26020 | 22629789 | Eksp Klin Gastroenterol | [UDCA in the treatment of nonalcoholic fatty liver disease]. | 2011 | Details |
| A26021 | 22629725 | Eksp Klin Gastroenterol | [UDCA in the treatment of nonalcoholic fatty liver disease]. | 2011 | Details |
| A26169 | 20965162 | Eur J Pharmacol | The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. | 2010 | Details |
| A26176 | 20955440 | Aliment Pharmacol Ther | Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. | 2010 | Details |
| A26190 | 20938947 | Hepatology | Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. | 2010 | Details |
| A26245 | 20842602 | Swiss Med Wkly | Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. | 2010 | Details |
| A26254 | 20828853 | J Hepatol | Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. | 2010 | Details |
| A26370 | 20578268 | Hepatology | A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. | 2010 | Details |
| A26404 | 23148155 | Ther Adv Endocrinol Metab | Advances in the treatment of nonalcoholic fatty liver disease. | 2010 | Details |
| A26422 | 20485253 | Minerva Gastroenterol Dietol | Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. | 2010 | Details |
| A26441 | 20460917 | Dig Dis | Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis. | 2010 | Details |
| A26483 | 20388946 | J Physiol Pharmacol | Therapy of nonalcoholic fatty liver disease: current status. | 2009 | Details |
| A26556 | 20210788 | Basic Clin Pharmacol Toxicol | Hepatic effects of rosiglitazone in rats with the metabolic syndrome. | 2010 | Details |
| A26623 | 20079722 | Chem Biol Interact | Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. | 2010 | Details |
| A26709 | 19921118 | Adv Ther | Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. | 2009 | Details |
| A26761 | 19818312 | Clin Liver Dis | Pharmacologic therapy of non-alcoholic steatohepatitis. | 2009 | Details |
| A26791 | 19779336 | Curr Opin Lipidol | Thiazolidinediones and the liver in humans. | 2009 | Details |
| A26842 | 19670918 | Drug Saf | Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. | 2009 | Details |
| A26844 | 19667999 | Eur J Gastroenterol Hepatol | Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. | 2010 | Details |
| A26984 | 19412008 | J Pediatr Gastroenterol Nutr | Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. | 2009 | Details |
| A27014 | 19353360 | Ann Med | New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). | 2009 | Details |
| A27130 | 21180532 | Therap Adv Gastroenterol | Current status of therapy in nonalcoholic Fatty liver disease. | 2009 | Details |
| A27148 | 19084941 | World J Gastroenterol | Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. | 2008 | Details |
| A27163 | 19065650 | Hepatology | Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. | 2009 | Details |
| A27215 | 18957882 | Curr Opin Lipidol | The trials and tribulations of the treatment of nonalcoholic fatty-liver disease. | 2008 | Details |
| A27218 | 18956296 | Semin Liver Dis | Current and emerging therapies in nonalcoholic fatty liver disease. | 2008 | Details |
| A27258 | 18822121 | BMC Mol Biol | Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. | 2008 | Details |
| A27265 | 18804555 | Contemp Clin Trials | Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. | 2008 | Details |
| A27358 | 18564173 | Diabetes Obes Metab | Current treatment of non-alcoholic fatty liver disease. | 2008 | Details |
| A27369 | 18516264 | Ther Clin Risk Manag | Treatment of non-alcoholic fatty liver disease. | 2007 | Details |
| A27411 | 18445142 | Aliment Pharmacol Ther | Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. | 2008 | Details |
| A27417 | 18422468 | Expert Opin Pharmacother | Pleiotropic effects of thiazolidinediones. | 2008 | Details |
| A27421 | 18417155 | Life Sci | The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. | 2008 | Details |
| A27532 | 18176372 | Gastroenterol Clin Biol | [Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome]. | 2007 | Details |
| A27537 | 18171348 | J Gastroenterol Hepatol | PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. | 2008 | Details |
| A27587 | 17983937 | Endocrinol Metab Clin North Am | Use of insulin sensitizers in NASH. | 2007 | Details |
| A27597 | 17950097 | Metabolism | Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. | 2007 | Details |
| A27603 | 17928738 | J Pharmacol Sci | Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. | 2007 | Details |
| A27676 | 17691915 | Curr Drug Discov Technol | Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). | 2007 | Details |
| A27695 | 17654601 | Hepatology | Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. | 2007 | Details |
| A27702 | 17619535 | Acta Gastroenterol Belg | Pathogenesis of steatohepatitis: insights from the study of animal models. | 2007 | Details |
| A27723 | 17560678 | J Hepatol | Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. | 2007 | Details |
| A27743 | 17542283 | Rev Gastroenterol Mex | [Therapeuric aspects of NAFLD. A literature review]. | 2007 | Details |
| A27868 | 17203528 | World J Gastroenterol | Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. | 2006 | Details |
| A27893 | 17073635 | Curr Med Chem | Current pharmacological treatment of nonalcoholic fatty liver. | 2006 | Details |
| A27931 | 16968800 | J Clin Endocrinol Metab | Review: The role of insulin resistance in nonalcoholic fatty liver disease. | 2006 | Details |
| A27932 | 16959622 | J Formos Med Assoc | Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. | 2006 | Details |
| A27964 | 16865780 | World J Gastroenterol | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. | 2006 | Details |
| A27968 | 16845716 | J Zhejiang Univ Sci B | Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. | 2006 | Details |
| A27984 | 16796890 | Zhonghua Yi Xue Za Zhi | [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats]. | 2006 | Details |
| A28044 | 16610015 | World J Gastroenterol | Treatment of nonalcoholic fatty liver disease. | 2006 | Details |
| A28059 | 16540770 | J Clin Gastroenterol | Therapy of NAFLD: insulin sensitizing agents. | 2006 | Details |
| A28077 | 16503761 | Expert Opin Investig Drugs | Recent findings concerning thiazolidinediones in the treatment of diabetes. | 2006 | Details |
| A28079 | 16672828 | J Clin Gastroenterol | Therapy of NAFLD: Insulin Sensitizing Agents. | 2006 | Details |
| A28112 | 16393299 | Aliment Pharmacol Ther | Review article: Drug therapy for non-alcoholic fatty liver disease. | 2006 | Details |
| A28144 | 16268963 | Aliment Pharmacol Ther | Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. | 2005 | Details |
| A28145 | 16265156 | Nat Clin Pract Gastroenterol Hepatol | Treatment strategies in nonalcoholic fatty liver disease. | 2005 | Details |
| A28156 | 16250043 | Hepatology | Insulin resistance: a metabolic pathway to chronic liver disease. | 2005 | Details |
| A28159 | 16247633 | Internist (Berl) | [Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis]. | 2005 | Details |
| A28165 | 16231594 | Eur Rev Med Pharmacol Sci | The treatment of NAFLD. | 2006 | Details |
| A28319 | 15696851 | Scand J Gastroenterol Suppl | Non-alcoholic fatty liver disease: a brief review. | 2004 | Details |
| A28346 | 15561641 | Best Pract Res Clin Gastroenterol | Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. | 2004 | Details |
| A28426 | 15046183 | Dig Liver Dis | Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? | 2004 | Details |
| A28428 | 15017657 | Clin Gastroenterol Hepatol | Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. | 2003 | Details |
| A28430 | 15013444 | Biochem Biophys Res Commun | Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. | 2004 | Details |
| A28459 | 14585234 | Curr Treat Options Gastroenterol | Treatment of Nonalcoholic Fatty Liver Disease. | 2003 | Details |
| A28479 | 12739988 | Expert Opin Pharmacother | Current best treatment for non-alcoholic fatty liver disease. | 2003 | Details |
| A28565 | 10902968 | Liver | The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. | 2000 | Details |
| A29546 | 33903842 | Cureus | Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series. | 2021 | Details |
| A30134 | 32923834 | Hepatol Commun | The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. | 2020 | Details |
| A30694 | 31960563 | Liver Int | Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes. | 2020 | Details |
| A34203 | 24126564 | Nat Rev Gastroenterol Hepatol | Pharmacological agents for NASH. | 2013 | Details |
| A34685 | 22882855 | Chin Med J (Engl) | Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats. | 2012 | Details |
| A35111 | 21711428 | Hepatol Res | Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones? | 2011 | Details |
| A35412 | 20810317 | Curr Opin Pharmacol | Mechanisms of adiponectin regulation and use as a pharmacological target. | 2010 | Details |
| A35444 | 20662773 | Aliment Pharmacol Ther | Pioglitazone in the treatment of NASH: the role of adiponectin. | 2010 | Details |
| A35530 | 20427778 | N Engl J Med | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. | 2010 | Details |
| A35552 | 20376096 | Gene Ther | PPARgamma is essential for protection against nonalcoholic steatohepatitis. | 2010 | Details |
| A35700 | 19877169 | Hepatology | Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. | 2010 | Details |
| A35799 | 19670459 | Hepatology | Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. | 2009 | Details |
| A35964 | 19318980 | J Clin Gastroenterol | Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? | 2009 | Details |
| A36013 | 19205029 | Hepatology | Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. | 2009 | Details |
| A36019 | 19195626 | Diabetes Metab | Insulin resistance and steatosis in humans. | 2008 | Details |
| A36112 | 18991162 | Scand J Gastroenterol | Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. | 2009 | Details |
| A36214 | 18718471 | Gastroenterology | Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. | 2008 | Details |
| A36297 | 18503774 | Gastroenterology | Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. | 2008 | Details |
| A36597 | 17661371 | Hepatology | The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. | 2007 | Details |
| A36622 | 17594812 | Zhonghua Gan Zang Bing Za Zhi | [An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis]. | 2007 | Details |
| A36637 | 17559148 | Hepatology | The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. | 2007 | Details |
| A36699 | 17436085 | Dig Dis Sci | Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. | 2007 | Details |
| A36710 | 17410441 | Dig Dis Sci | Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. | 2007 | Details |
| A36751 | 17335677 | Curr Gastroenterol Rep | Treatment of fibrosis in nonalcoholic fatty liver disease. | 2007 | Details |
| A36801 | 17241878 | Gastroenterology | Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. | 2006 | Details |
| A36967 | 16814613 | Clin Gastroenterol Hepatol | Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. | 2006 | Details |
| A36989 | 16768125 | Nihon Rinsho | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. | 2006 | Details |
| A36990 | 16768123 | Nihon Rinsho | [Drug therapy for non-alcoholic steatohepatitis]. | 2006 | Details |
| A36994 | 16768114 | Nihon Rinsho | [PPAR and NASH]. | 2006 | Details |
| A37238 | 16198619 | Hepatol Res | Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection. | 2005 | Details |
| A37322 | 15959406 | Ann Endocrinol (Paris) | [Nonalcoholic steatohepatitis]. | 2005 | Details |